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ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to re-evaluate the safety in use of vitamin D and to provide, if necessary, revised Tolerable Upper Intake 
Levels  (ULs)  of  vitamin  D  for  all  relevant  population  groups.  The  ULs  for  adults  including  pregnant  and 
lactating women, children and adolescents were revised. For adults, hypercalcaemia was selected as the indicator 
of toxicity. In two studies in men, intakes between 234 and 275 µg/day were not associated with hypercalcaemia, 
and  a  no  observed  adverse  effect  level  (NOAEL)  of  250 µg/day  was  established.  Taking  into  account 
uncertainties associated with these studies, the UL for adults including pregnant and lactating women was set at 
100 µg/day. Despite a continuing paucity of data for high vitamin D intakes in children and adolescents, the UL 
was adapted to 100 µg/day for ages 11-17 years, considering that owing to phases of rapid bone formation and 
growth this age group is unlikely to have a lower tolerance for vitamin D compared to adults. The same applies 
also to children aged 1-10 years, but taking into account their smaller body size, a UL of 50 µg/day is proposed. 
For infants, the UL of 25 µg/day based on previously available data relating high vitamin D intakes to impaired 
growth and hypercalcaemia was retained as limited additional evidence has emerged since the previous risk 
assessment. Data on vitamin D intakes from surveys in 14 European countries indicate that intakes  in high 
consumers  are  below  the  revised  ULs  for  vitamin  D  for  all  population  groups.  ©  European  Food  Safety 
Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to re-evaluate the safety in use of vitamin D and to provide, if necessary, revised 
Tolerable Upper Intake Levels (ULs) of vitamin D for all relevant population groups. 
Vitamin D derives from the diet but can also be synthesised in the skin under the influence of UV-B 
radiation. Serum 25(OH)D concentration is a good marker of vitamin D status, but can only be used 
as a biomarker of vitamin D intake in people with low exposure to sunlight. Following ingestion of 
large doses of vitamin D, the concentration of 25(OH)D in serum increases, while that of the active 
metabolite 1,25(OH)2D is unchanged or even reduced. Very high serum 25(OH)D concentrations 
may lead to hypercalcaemia, which is considered the critical effect of excess intake of vitamin D. 
Hypercalciuria can be associated with hypercalcaemia, but it can also occur without. 
For the derivation of the UL, the occurrence of hypercalcaemia and hypercalciuria has been assessed 
in studies using daily or weekly supplementation of vitamin D for several weeks to months. The 
shorter-term studies were generally performed in seasons of low sun exposure. Study populations 
were  not  generally  vitamin D-deficient, and two studies were conducted in subjects with a high 
vitamin D status at baseline. Study populations included whites, African Americans, young men, pre- 
and postmenopausal women, elderly nursing home residents, and overweight and obese adults. It was 
concluded that vitamin D at doses up to 275 µg/day does not lead to persisting hypercalcaemia or 
hypercalciuria in adults.  
Long-term health outcomes (all-cause mortality, cardiovascular disease, cancer, fractures and kidney 
stones) were also considered, but no studies reported an association between vitamin D intake and 
increased risk for adverse long-term health outcomes. Studies reporting on an association between 
25(OH)D  concentration  and  all-cause  mortality  or  cancer  were  inconsistent.  When  25(OH)D 
concentrations were associated with an increased risk for adverse long-term health outcomes in some 
studies, there was a wide variation in 25(OH)D concentrations associated with the adverse effect. It 
was  considered that  25(OH)D concentrations cannot be used to characterise the risk for adverse 
long-term health outcomes.  
In adults, a daily vitamin D dose of 250 µg/day (range 234-275 µg/day) was considered to reflect a 
no observed  adverse  effect  level  (NOAEL).  This  value  was  based  on  only  two  studies  of  short 
duration (up to five months) in small samples of healthy young men with minimal sun exposure. To 
take into account the uncertainties associated with this value, an uncertainty factor of 2.5 was chosen, 
and the UL was established at 100 µg/day. It was considered that the UL of 100 µg/day for adults 
also applies to pregnant and lactating women. This UL is supported by two studies in pregnant and 
lactating women, both using doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, 
which did not report adverse events for either the mothers or their offspring. 
For infants, there is historical evidence on retarded growth from a study in which infants received 
various regimens of vitamin D exceeding 45 µg/day up to one year of age, although another small 
study using doses up to 54 µg vitamin D/day until about five months of age did not show such an 
effect. More recent intervention studies using doses up to 25 µg vitamin D/day (plus the amount 
ingested via fortified infant formula) for up to five months after birth did not indicate that these 
intakes  are  associated  with  hypercalcaemia  in  infants.  As  new  data  from  intervention  studies  in 
healthy infants have not become available since the previous risk assessment by the SCF (2003), it 
was decided that the UL of 25 µg vitamin D/day previously derived for infants from 0 to 12 months 
of age should be retained. 
For children and adolescents aged 10-17 years, there is limited evidence from two studies showing 
that vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia. While there are no Tolerable Upper Intake Level of vitamin D 
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studies at higher intakes, it was considered that there is no reason to believe that adolescents in the 
phase of rapid bone formation and growth have a lower tolerance for vitamin D compared to adults, 
and a UL of 100 µg/day for adolescents aged 11-17 years was proposed. 
For children aged 1-10 years, no new data from intervention studies have emerged since the previous 
risk assessment. It was considered that there is no reason to believe that children aged 1-10 years in 
the phase of rapid bone formation and growth have a lower tolerance for vitamin D compared to 
adults, and, by taking into account their smaller body size, a UL for vitamin D of 50 µg/day was 
proposed. 
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups (i.e., about 25 %, 75 %, 30 % and 8 % of the UL for 
adults, infants, children and adolescents, respectively).  
 Tolerable Upper Intake Level of vitamin D 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Vitamin D has been assessed in the past by the Scientific Committee on Food. In the Opinion on the 
Tolerable Upper Intake Level (UL) of vitamin D of 4 December 2002 the Committee set the following 
UL values for vitamin D: 
  50  g vitamin D/day for adults; 
  25  g vitamin D/day for infants 0-2 years of age; 
  25  g vitamin D/day for children from 3-10 years of age; 
  50  g vitamin D/day for adolescents 11-17 years of age. 
On 30 November 2010, the American Institute of Medicine (IoM) published a report on “Dietary 
Reference Intakes for Calcium and Vitamin D” (IoM, 2010). In this report, the IoM proposes new 
reference values and UL values for vitamin D which, as stated in the report “are based on much more 
information and higher-quality study results than were previously available”.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission 
asks the European Food Safety Authority to: 
-  re-evaluate the safety in use of vitamin D,  
-  if necessary, provide revised tolerable upper intake levels, that are unlikely to pose a risk of 
adverse health effects, for vitamin D for all relevant population groups. Tolerable Upper Intake Level of vitamin D 
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ASSESSMENT 
1.  Introduction 
The principal physiological function of vitamin D in all vertebrates including humans is to maintain 
serum  calcium  and  phosphorus  concentrations  in  a  range  which  supports  cellular  processes, 
neuromuscular function, and bone ossification.  
It has become increasingly apparent that vitamin D also has other important functions in tissues not 
primarily related to mineral metabolism (Bouillon et al., 2008; Holick, 2006). Examples are its role in 
modulating the renal production of renin and its role in insulin secretion. The active metabolite, 
1,25(OH)2D, regulates the transcription of a large number of genes through binding to a transcription 
factor, the vitamin D receptor.  
In 2003, the Scientific Committee on Food (SCF, 2003) established a Tolerable Upper Intake Level 
(UL) of vitamin D for adults, including pregnant and lactating women, of 50 µg/day. This UL was 
based on the increased risk of hypercalcaemia observed after intakes of around 100 µg vitamin D/day 
in the highest dose group in one (Narang et al., 1984) of three studies. An uncertainty factor of 2 was 
applied to account for inter-individual variation. For infants and young children aged 0-24 months the 
UL was set at 25 µg/day based on the absence of hypercalcaemia attributable to intervention with 
vitamin D in two studies in which breast-fed or formula-fed infants received 25 µg vitamin D/day 
(plus the amount ingested via fortified infant formula) for some months. The UL for children aged 
3-10 years was set at 25 µg/day and for adolescents aged 11-17 years at 50 µg/day, though data on 
supplementation with vitamin D doses ≥20 µg/day were lacking.  
The UL for vitamin D for adults established by the SCF (2003) was 50 µg/day, the same as that from 
the US Institute of Medicine (IoM, 1997). It was derived from a no observed adverse effect level 
(NOAEL) of 60 µg/day, by applying an uncertainty factor of 1.2 to account for the small sample size 
and short duration of the single study (Narang et al., 1984) on which the NOAEL was based. The 
same UL of 50 µg/day was set for pregnant and lactating women and for children beyond one year of 
age. For infants, a UL of 25 µg/day was set based on normal growth in formula-fed infants ingesting 
34.5-54.3 µg vitamin D/day, by applying an uncertainty factor of 1.8 to the mean of the lower and 
upper dose range (44.4 µg) to account for the insensitivity of the end point and the small sample size 
of the study. 
In 2011, the IoM published its re-assessment of the UL for vitamin D and considered an intake of 
250 µg vitamin D/day as a NOAEL, but also used information on 25(OH)D concentrations achieved 
during considerable sun exposure as well as evidence from observational studies on chronic disease 
outcomes  suggesting  an  increase  in  risk  associated  with  25(OH)D  concentrations  above 
approximately  125  to  150 nmol/L.  Based  on  one  dose-response  study,  vitamin  D  intakes  of 
125 µg/day  were  judged  as  not  increasing  25(OH)D  concentration  beyond  150 nmol/L.  An 
uncertainty factor of 1.2 was applied to take into account various uncertainties and the reliance on a 
single study. The UL for adults, including pregnant and lactating women, was set at 100 µg/day. The 
same UL was set for children and adolescents aged 9-18 years, while the value was scaled down for 
young children and those aged 4-8 years. For infants aged 0-6 months, a UL of 25 µg/day was set 
based  on  normal  growth  in  infants  receiving  a  mean  of  44.4 µg  vitamin  D/day,  applying  an 
uncertainty factor of 2 to ensure absence of toxicity also in small infants, and then rounding. In infants 
aged 6-12 months with a greater body size, the UL was set at 38 µg/day (IoM, 2010).  Tolerable Upper Intake Level of vitamin D 
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This opinion relates to the evaluation of the safety in use of vitamin D forms authorised for addition 
to foods
4 or food supplements
5, i.e. cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). The 
two forms only differ by their side chains on the sterol skeleton (Holick, 2006). The term vitamin D 
without a subscript relates to either or both vitamin D2 or vitamin D3 and its metabolites. Only data on 
oral intake of vitamin D will be considered for this opinion. 
2.  Dietary intakes 
Few foods naturally contain vitamin D. Some higher fungi such as mushrooms are a natural source of 
vitamin D2. Animal foods such as fatty fish, liver, fish liver oils and egg yolks contain vitamin D3. 
Further  sources  of  vitamin  D  are  fortified  foods  (most  often  milk,  margarine  and/or  butter,  and 
breakfast cereals) and dietary supplements.  
Mean intakes of vitamin D in European countries vary according to sex, age, and supplementation 
habits  (Appendices  A  and  B).  There  is  a  large  diversity  in  the  methodology  used  to  assess  the 
individual  intakes  of  children,  adolescents  and  adults.  These  differences  in  dietary  assessment 
methods make direct comparisons difficult. Data from Poland based on a single 24-h recall have been 
listed  in  Appendices  A  and  B  for  completeness  but  have  not  been  considered  in  the  text.  Age 
classifications  may  not  be  uniform  and  comparability  is  also  hindered  by  differences  in  food 
composition  tables  used  for  the  conversion  of  food  consumption  data  to  nutrient  intake  data 
(Deharveng  et  al.,  1999).  Although  these  differences  have  an  impact  on  the  accuracy  of 
between-country comparisons, the data presented give a rough overview of average vitamin D intakes 
and intakes in high consumers in a number of European countries. 
2.1.  Adults 
Mean intakes of vitamin D from foods only varied from 1.1 µg/day (Spain, women, 18-64 years) to 
8.2 µg/day  (Finland,  men,  25-74  years).  The  95
th  percentiles  varied  between  2.4 µg/day  (Spain, 
women, 18-64 years) and 16.0 µg/day (Finland, men, 25-74 years).  
When  foods  and  supplements  were  considered  together,  mean  intakes  of  vitamin  D  varied  from 
3.1 µg/day  (Ireland, women, 18-35 years) to  23.5 µg/day (Norway, men in the fourth quartile  of 
n-3 long-chain polyunsaturated fatty acid intake, 16-79 years). Intakes at the 95
th percentile varied 
between 6.3 µg/day (The Netherlands, women, 19-30 years) and 24.2 µg/day (Ireland, ≥65 years).  
The  Panel  notes  that  the  range  of  vitamin  D  intakes  reported  from  14  European  countries  is 
considerable. In high consumers (95
th percentile), intakes from foods are up to 16 µg/day, and about 
1.5-fold this value in those that consume supplements in addition to foods.  
2.2.  Infants (≤1 year) 
For  infants,  mean  intakes  from  foods  and  supplements  were  available  from  Finland  and  The 
Netherlands,  and  varied  between  8.9 µg/day  (The  Netherlands,  1  year)  and  12.5 µg/day  (The 
Netherlands, 0.75 years). The 90
th percentiles were between 14.8 and 19.3 µg/day in Dutch infants 
aged 1 and 0.75 years, respectively. The high percentiles available for Finland (P75) were within this 
range.  
                                                       
4  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26-38. 
5  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.07.2002, p. 51-57. Tolerable Upper Intake Level of vitamin D 
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2.3.  Children (approximately 1-14 years) 
In younger children, mean intakes from foods varied from 1.7 µg/day (Denmark, boys, 1-3 years) to 
5.6 µg/day (Greece, 1-5 years). The values for high percentiles were between 2.4 µg/day (Denmark, 
P95, boys, 1-3 years) and 11.9 µg/day (Greece, P90, 1-5 years). Mean vitamin D intakes from foods 
and supplements varied from 2.3 µg/day (UK, 1.5-3 years) to 9.0 µg/day (Finland, girls, 2 years). The 
90
th percentile in Dutch children  aged 1.5 years was 8.1 µg/day. The high percentiles available for 
Finland (P75) were even higher, i.e. 9.5 and 12.6 µg/day in boys and in girls, aged 2 or 3 years. 
In older children, mean or median intakes from foods only varied from  1.4 µg/day (mean, Spain, 
4-10 years;  Ireland,  boys,  5-12  years)  to  2.7 µg/day  (The  Netherlands,  median,  boys, 9-13 years). 
Intakes at the 95
th percentile were between 2.9 µg/day (Spain, 4-10 years, including fortified food) 
and 5.9 µg/day (Denmark, 4-14 years). Average intakes from foods and supplements varied from 
1.8 µg/day (mean, Germany, 6-11 years; Spain, 4-10 years) to 6.6 µg/day (Sweden, mean, 4 years). 
Intakes at the 95
th percentile were between 3.0 µg/day (Spain, 4-10 years) and 15.4 µg/day (Sweden, 
4 years). 
2.4.  Adolescents 
In adolescents, mean intakes from foods varied from 1.6 µg/day (Spain, 11-17 years) to 4.0 µg/day 
(Belgium,  boys  13-18  years).  Intakes  at  the  95
th  percentile  were  between  3.0 µg/day  (Spain, 
11-17 years) and 7.7 µg/day (Italy, boys, 10-<18 years, including fortified food). Mean or median 
intakes  from  foods  and  supplements  and  for  the  95
th  percentile  of  consumption  are  within  these 
ranges. 
The Panel notes that in infants, children and adolescents from 11 European countries, the highest 
intakes  from  foods  and  supplements  are  observed  in  infants  (up  to  about  19  µg/day  at  the 
90
th percentile), while the intake in high consumers is lower in children (up to about 15 µg/day at the 
95
th percentile) and even lower in adolescents (up to about 8 µg/day at the 95
th percentile).  
3.  Hazard identification 
3.1.  Vitamin D physiology 
Vitamin D derives from diet but can also be synthesised in the skin from 7-dehydrocholesterol under 
the  influence  of  UV-B  radiation  (290–315 nm  wavelengths),  leading  to  the  formation  of 
previtamin D3.  Previtamin  D3  thermally  isomerises  to  vitamin  D3  immediately  after  formation. 
Sunlight itself regulates the total production of vitamin D3 in the skin, as both previtamin D3 and 
vitamin D3 present in the skin are photodegraded to biologically inert isomers following prolonged 
UV-B exposure. Dietary intake of vitamin D increases 25(OH)D concentrations without an equivalent 
regulatory mechanism, with a linear relationship between vitamin D intakes and serum 25(OH)D 
concentrations  well  into  the  high  dose  range  (Holick,  2006).  The  24-hydroxylase  catabolises 
25(OH)D  to  24,25(OH)2D  to  prevent  its  eventual  activation  to  1,25(OH)2D  (Jones  et  al.,  2012). 
Following vitamin D supplementation, 24-hydroxylase is upregulated, though this adaptation occurs 
with a lag of several weeks (Wagner et al., 2011).  
Both 25- and 1α -hydroxylation of vitamin D are needed to form the active metabolite 1,25(OH)2D. 
At least  four  enzymes,  all  microsomal  cytochrome  P450  (CYP)  isoforms  (CYP2DII,  CYP2D25, 
CYP3A4, and CYP2R1), can accomplish the 25-hydroxylation of vitamin D in human hepatocytes. 
Little feedback is assumed for these 25-hydroxylases, and serum 25(OH)D concentration generally 
reflects vitamin D status. Serum 1,25(OH)2D, the active metabolite, is synthesised in the kidney, 
where the activity of the enzyme 25(OH)D-1α-hydroxylase (CYP27B1) is regulated by calcium and 
phosphate, as well as by their regulating hormones (calcium, parathyroid hormone, calcitonin, growth Tolerable Upper Intake Level of vitamin D 
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hormone,  and  insulin-like  growth  factor  I  being  positive  regulators;  phosphate,  fibroblast  growth 
factor 23, and 1,25(OH)2D itself being negative regulators). The active metabolite exerts its action 
through binding to the vitamin D receptor and activating a nuclear transcription factor (Bouillon et al., 
2008). 
The  principal  function  of  the  active  metabolite  (1,25(OH)2D)  is  to  maintain  intracellular  and 
extracellular  calcium  concentrations  within  a  physiologically  acceptable  range.  This  regulation  is 
accomplished by enhancing the efficiency of the small intestine  in absorbing dietary calcium and 
phosphorus, and by mobilising calcium and phosphorus from the bone. 
3.2.  Biomarkers of vitamin D intake 
The concentration of 25(OH)D in plasma or serum can only be used as a biomarker of vitamin D 
intake in people with low exposure to sunshine. After initiation of vitamin D supplementation, a new 
steady state is reached after six to eight weeks in adults (Seamans and Cashman, 2009). It has been 
suggested that whereas vitamin D2 and vitamin D3 may equally increase 25(OH)D concentrations 
when supplemented daily, vitamin D3 may raise 25(OH)D concentrations more than vitamin D2 if 
single or infrequent bolus doses are administered (Tripkovic et al., 2012). 
3.3.  Biomarkers of vitamin D status and activity 
There is consensus that serum 25(OH)D concentration is a good marker of vitamin D status (Seamans 
and  Cashman,  2009).  The  25(OH)D  denotes  both  D2  and  D3  metabolites.  Plasma 
25-hydroxyergocalciferol (25(OH)D2) is of exogenous origin only, while 25-hydroxycholecalciferol 
(25(OH)D3) may arise from either dietary intake or formation in the skin. Plasma concentration of 
1,25(OH)2D (particularly free 1,25(OH)2D) is a measure of vitamin D hormone activity, but because 
of tight homeostatic regulation, 1,25(OH)2D does not reflect vitamin D nutritional status. 
Owing to its slow turnover in the body (half-life of about two months (Jones, 2008), vitamin D is 
often  administered  weekly  in  equivalent  doses  instead  of  daily.  Depending  on  the  dose  and  the 
duration of supplementation, resulting 25(OH)D concentrations may be comparable (Ish-Shalom et 
al., 2008) or somewhat lower (Chel et al., 2008) with weekly compared to daily supplementation, 
respectively. 
The main determinants, besides intake, of vitamin D status are skin pigmentation and sun exposure. 
Concentrations of 25(OH)D vary according to season, with the lowest concentrations occurring at the 
end of winter and the highest concentrations in summer (Hintzpeter et al., 2008), generally reflecting 
the amount of endogenous synthesis following UV-B radiation. Latitude of residence and time of day 
also  determine  the  amount  of  UV-B  photons  penetrating  the  stratospheric  layer  and  resulting  in 
cutaneous  synthesis  of  previtamin  D3  in  exposed  skin  (Holick,  2006).  Below  a  latitude  of 
approximately 35° North, UV-B radiation is sufficient for vitamin D3 synthesis all year round. At 
higher latitudes, there is no cutaneous vitamin D3 synthesis during the winter months. For example, in 
Rome, Italy (latitude 41.9° North), cutaneous vitamin D3 synthesis is not possible from November 
through February. Ten degrees further north in Berlin, Germany (latitude 52.5° North) or Amsterdam, 
the  Netherlands  (latitude  52.4°  North),  vitamin  D3  synthesis  ceases  between  October  and  April 
(Tsiaras  and  Weinstock,  2011).  Vitamin  D  intoxication  by  UV-B  radiation  alone  has  not  been 
reported (Webb et al., 1989). Mean (range) 25(OH)D concentrations under sun-rich living conditions 
were 133 (27-277) nmol/L in 18 farmers in Puerto Rico (Haddock et al., 1982), 161 (132-197) nmol/L 
in eight lifeguards in St. Louis (USA) (Haddad and Chyu, 1971), and 133±84 nmol/L in 44 Israeli 
lifeguards  (Better  et  al., 1980). Following extended exposure to sunlight during summer, median 
(interquartile range) 25(OH)D concentrations in late summer were 122 (95–154) nmol/L in 26 young 
men for whom sun exposure was the principal source of vitamin D, with the highest concentration Tolerable Upper Intake Level of vitamin D 
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being 211 nmol/L. The median (interquartile range) seasonal difference in 25(OH)D concentration 
between late summer and late winter was 49 (29-67) nmol/L (Barger-Lux and Heaney, 2002).  
Further determinants of vitamin D status are age and body mass, with lower 25(OH)D concentrations 
observed in advanced age (Hintzpeter et al., 2008; Holick, 2006) and in obesity (Hintzpeter et al., 
2008; Kauppi et al., 2009; Macdonald et al., 2008; Snijder et al., 2005).   
The amount of vitamin D in human milk is modestly correlated with maternal vitamin D intakes up to 
about 18 µg/day, with evidence for a lower response in African-American compared to white women 
(Specker  et  al.,  1985).  Few  data  are  available  to  estimate  precisely  the  increase  in  human  milk 
vitamin D concentration in response to supplemental vitamin D (Ala-Houhala et al., 1986; Hollis and 
Wagner,  2004;  Specker  et  al.,  1985).  Infants  of  mothers  supplemented  with  50  or  100 µg 
vitamin D/day during months 1-4 of lactation only differed slightly in serum 25(OH)D concentration 
(Hollis and Wagner, 2004), pointing to a limitation of vitamin D transfer into human milk.   
3.4.  Mechanisms of toxicity 
Following ingestion of large doses of vitamin D, the concentration of 25(OH)D in serum increases, 
while that of the active metabolite 1,25(OH)2D is unchanged (Jones, 2008) or even reduced (IoM, 
2010).  However,  at  high  concentrations  of  25(OH)D  and  other  vitamin  D  metabolites  (such  as 
24,25(OH)2D3, 25,26(OH)2D3, and 25(OH)D3-26,23-lactone) the binding capacity of the vitamin D 
binding protein may be exceeded, leading to the release of unbound 25(OH)D and 1,25(OH)2D. It has 
been hypothesised that these free forms enter target cells and directly stimulate gene transcription 
(Bouillon  et  al.,  2008).  However,  severe  hypercalcaemia  and  weight  loss  after  administration  of 
vitamin  D  have  been  observed  in  a  mouse  model  which  is  unable  to  synthesise  1,25(OH)2D, 
suggesting that 25(OH)D rather than 1,25(OH)2D may be mediating toxicity (DeLuca et al., 2011). 
Very high serum 25(OH)D concentrations (which may displace 1,25(OH)2 D from vitamin D-binding 
protein)  may  lead  to  hypercalcaemia  (Holick,  2006;  Pettifor  et  al.,  1995;  Vieth,  1990),  which  is 
defined by serum calcium concentrations >2.75 mmol/L (11 mg/dL). Values used for the diagnosis of 
hypercalcaemia may change across laboratories and will be defined in this opinion according to the 
cut-off  selected  by  the  authors  in  each  individual  study.  Clinical  symptoms  associated  with 
hypercalcaemia are fatigue, muscular weakness, anorexia, nausea, vomiting, constipation, tachycardic 
arrhythmia, soft tissue calcification, failure to thrive, and weight loss. Hypercalcaemia may also lead 
to hypercalciuria, which is defined by a calcium excretion >0.3 mg/mg creatinine in 24-hour urine of 
adults, or as a calcium excretion >250 mg/day in women and >275-300 mg/day in men. Consequences 
of sustained hypercalcaemia are nephrolithiasis (kidney stones), nephrocalcinosis, and a decrease in 
kidney function (see also the Scientific Opinion on the  Tolerable Upper Intake Level of calcium 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2012). 
3.5.  Adverse effects of excess vitamin D intake 
3.5.1.  Vitamin D intake and hypercalcaemia in adults 
In 2003, the SCF derived a UL of 50 µg vitamin D/day for adults (SCF, 2003). In this section, new 
evidence which has become available since 2003 will be described in conjunction with the evidence 
used to derive the previous NOAEL of 100 µg vitamin D/day for adults. Intervention studies in which 
vitamin D was administered weekly or more frequently in doses equivalent to intakes between 60 and 
1,269 µg/day,  and  which  reported  on  serum  calcium  concentrations  and/or  the  occurrence  of 
hypercalcaemia, have been considered (see also Appendix C). Tolerable Upper Intake Level of vitamin D 
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Studies with vitamin D doses up to 275 µg/day 
A  number  of  intervention  studies  in  humans  have  reported  on  the  effects  of  vitamin  D 
supplementation at doses up to 275 µg/day on calcaemia and calciuria (Appendix C). Several studies 
monitored serum calcium concentrations at several time points throughout the study and addressed 
possible  adverse  effects  as  secondary  outcomes.  The  majority  of  the  studies  were  randomised 
controlled trials (RCTs) in which vitamin D supplementation was compared to a placebo (Aloia et al., 
2008; Gallagher et al., 2012; Heaney et al., 2003; Jorde et al., 2010; Sneve et al., 2008; Zittermann et 
al., 2009) or to a lower dose of vitamin D (Grimnes et al., 2012; Narang et al., 1984; Vieth et al., 
2001).  One  was  a  dose-response  study  using  four  different  doses  of  vitamin  D  in  the  range  of 
0-275  g/day (Heaney et al., 2003). One controlled study was not randomised (Berlin et al., 1986; 
Berlin and Björkhem, 1987), one was a two-arm intervention with no control group (Tjellesen et al., 
1986), and one was a one-arm intervention with no control group (Mocanu et al., 2009). Considering 
only the highest dose in studies using multiple doses, the equivalent daily vitamin D doses ranged 
from 83 to 275 µg, and the duration of the supplementation from seven weeks to 12 months. In 
addition to vitamin D, subjects received supplemental calcium in five studies: four studies used doses 
ranging from 320 to 1,000 mg/day (Grimnes et al., 2012; Jorde et al., 2010; Mocanu et al., 2009; 
Tjellesen et al., 1986), while supplemental calcium intake was adjusted individually to achieve a total 
calcium intake of 1,200-1,400 mg/day in the study by Gallagher et al. (2012). The shorter-term studies 
were  generally  performed  in  seasons  of low sun exposure. Study populations were not generally 
vitamin D-deficient, and two studies (Grimnes et al., 2012; Heaney et al., 2003) were conducted in 
subjects  with  a  high  vitamin  D  status  at  baseline.  Study  populations  included  whites,  African 
Americans,  young  men,  pre-  and  postmenopausal  women,  elderly  nursing  home  residents,  and 
overweight and obese adults.  
The study by Narang et al. (1984) reported mean serum calcium concentrations to be slightly above 
the normal range in the few subjects who received the highest vitamin D dose (95 µg/day). The Panel 
notes that these results are not in line with the findings of studies using similar or (much) higher doses 
of vitamin D. The Panel also notes that this study did not include a true (non-vitamin D) control 
group, and that no information on serum 25(OH)D concentration, season of the trial, background 
vitamin D intake and persistance of elevated serum calcium concentration was provided.  
In the dose-response study by Heaney et al. (2003), in which men received either 0, 20.9, 137.5 or 
275 µg vitamin D3/day for 20 weeks, mean serum calcium concentrations measured at five time points 
during  the  study  in  the  two  groups  receiving  the  highest  doses  of  vitamin  D  did  not  change 
significantly from baseline and remained below the upper limit of normal (<2.6 mmol/L) for all of the 
31 subjects in these groups. 
None of the remaining studies reported persisting or occasional hypercalcaemia and/or hypercalciuria 
which could be attributed to vitamin D supplementation. The Panel notes that several studies used 
doses of vitamin D >95  g/day.  
The  Panel  concludes  that  vitamin  D  at  doses  up  to  275 µg/day  do  not  lead  to  persisting 
hypercalcaemia or hypercalciuria in adults. 
Studies with vitamin D doses >275 µg/day 
In an open-label study, Barger-Lux et al. (1998) administered 35, 234 or 1,269  g vitamin D3/day for 
eight weeks to 38 men (n=14 in the highest dose group). The authors stated that post-treatment testing 
indicated absence of hypercalcaemia in vitamin D3-supplemented subjects, but no further information, 
including a definition of hypercalcaemia, was given. The Panel notes that the serum concentrations of 
25(OH)D reported in this study for the highest dose group (about 710 nmol/L) were far above those 
observed  following  considerable  sun  exposure  (serum  25(OH)D  concentration  between  around 
120 and 160 nmol/L, see Section 3.3).  Tolerable Upper Intake Level of vitamin D 
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Hypercalcaemia owing to high intakes of vitamin D in dietary supplements (e.g. Araki et al. (2011); 
Lowe et al. (2011)) or in milk (Blank et al., 1995; Jacobus et al., 1992) has been reported. Doses of 
vitamin D and duration of supplementation cannot be estimated precisely from these case reports.  
In  some  studies,  higher  doses  of  vitamin  D  (twice  weekly  administration  equivalent  to  321 µg 
vitamin D2/day, 450 µg vitamin D2/day) were part of the treatment regimen for various diseases, and 
its  use  for  weeks  to  years  was  not  associated  with  increased  serum  calcium  concentrations  or 
hypercalcaemic episodes (Hasling et al., 1987; Rickers et al., 1982). However, these findings are 
difficult  to  interpret  because  of  the  concomitant  administration  of  substances  that  may  have 
confounded the outcome (e.g. prednisone and/or sodium fluoride), and because of the use in small 
groups  of  patients  with  various  diseases.  For  the  same  reasons,  evidence  from  case  reports  of 
vitamin D  intoxication  after  administration  of  vitamin  D  for  the  treatment  of  osteoporosis, 
osteomalacia, hypoparathyroidism or other diseases (Davies and Adams, 1978; Rizzoli et al., 1994; 
Schwartzman  and  Franck,  1987;  Selby  et  al.,  1995)  (see  Appendix  C)  cannot  be  used  for  the 
establishment of a UL for healthy adults. 
The Panel notes that the data available from these studies and case reports on vitamin D at intakes 
>275 µg/day are not suitable for establishing a UL for long-term intakes.  
3.5.2.  Serum 25(OH)D concentration and hypercalcaemia in adults 
Following supplementation with up to 275 µg vitamin D3/day for 20 weeks, Heaney et al. (2003) 
observed a mean 25(OH)D concentration of about 220 nmol/L without concomitant hypercalcaemia.  
Vieth (1999) reviewed case reports of vitamin D toxicity and concluded that hypercalcaemia owing to 
vitamin D intoxication per se is always accompanied by serum 25(OH)D concentrations >220 nmol/L. 
Other reviews suggested that hypercalcaemia only resulted at 25(OH)D concentrations consistently 
exceeding 375-500 nmol/L (Jones, 2008), or ≥700 nmol/L in normal adults (Hathcock et al., 2007). In 
four  cases  of  vitamin  D  intoxication  in  osteoporotic  women,  25(OH)D  concentrations  between 
339 and 804 nmol/L were observed during the course of diagnosis and treatment (Schwartzman and 
Franck, 1987). Araki et al. (2011) reported hypercalcaemia in two cases of vitamin D intoxication 
following ingestion of erroneously manufactured and labelled vitamin D supplements; both patients 
became  normocalcaemic  and  asymptomatic  once  25(OH)D  concentrations  decreased  below 
998 nmol/L.  In  19  case  reports  on  hypercalcaemia,  serum  25(OH)D  concentrations  of 
533-1,692 nmol/L were reported after a daily vitamin D intake between 1,250 µg and 7,500 µg for 
three weeks to several years  (Davies and Adams, 1978; Rizzoli et al., 1994; Selby et al., 1995); 
however, one woman who presented with hypercalcaemia after receiving the equivalent of 2,143 µg 
vitamin D3/day for 96 weeks had a plasma 25(OH)D concentration of only 221 nmol/L (Rizzoli et al., 
1994). 
The Panel concludes that 25(OH)D concentrations associated with hypercalcaemia vary over a wide 
range,  and  that  the  25(OH)D  concentration  in  serum  or  plasma  cannot  be  considered  a  suitable 
predictor of hypercalcaemia.  
3.5.3.  Vitamin D intake or status and long-term health outcomes in adults 
A  wealth  of  observational  and  intervention  studies  has  been  performed  in  recent  years  on  the 
association between vitamin D intake or status and various chronic diseases. The studies generally 
adjusted for season. Most of the observational studies (Anderson et al., 2010; Cawthon et al., 2010; 
Eaton et al., 2011; Ford et al., 2011; Ginde et al., 2009; Hutchinson et al., 2010; Jia et al., 2007; 
Semba et al., 2009; Semba et al., 2010; Virtanen et al., 2011; Visser et al., 2006) aimed at evaluating 
the role of vitamin D insufficiency as a risk factor, but some also took into account potential adverse Tolerable Upper Intake Level of vitamin D 
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effects of high serum 25(OH)D concentrations or high vitamin D intake and allowed for non-linear 
associations when analysing relationships.  
Of  these,  some  observational  studies  found  a  U-shaped  or  reverse  J-shaped  association  between 
25(OH)D concentrations and all-cause mortality, with a significant increase in risk in elderly Swedish 
men with concentrations >98 nmol/L (but not >93 nmol/L)  (Michaelsson et al., 2010) and in US 
females (but not in men or both sexes combined) with concentrations >124.8 nmol/L (Melamed et al., 
2008). In some studies, the higher risk associated with the highest 25(OH)D concentrations did not 
hold for longer times of follow-up (Johansson et al., 2011) or did not consider important possible 
confounders  such  as  smoking,  body  mass  index  (BMI)  and  health  status  (Durup  et  al.,  2012). 
Evidence from a meta-analysis of randomised primary and secondary prevention trials which provided 
data  for  mortality  analyses  showed  that  a  dose  ≥20 µg  vitamin  D3/day  (n=21  studies)  or  ≥20 µg 
vitamin D2/day  (n=12  studies)  administered  over  a  median  of  two  years  did  not  affect  all-cause 
mortality (Bjelakovic et al., 2011). These results are in line with findings of another meta-analysis 
that  did  not  observe  an  effect  of  vitamin  D  doses  ≥20 µg/day  on  mortality  as  observed  in 
20 randomised trials (Elamin et al., 2011). 
Some studies performed subgroup analyses according to the cause of death. A significant increase in 
total  cancer  mortality  was  observed  in  Swedish  elderly  men  with  baseline  serum  25(OH)D 
concentrations >98 nmol/L (but not >93 nmol/L) (Michaelsson et al., 2010), and in US men (but not 
in  women)  with  25(OH)D  concentrations  in  the  highest  two  categories  (80-<100 nmol/L  and 
≥100 nmol/L) compared to men with 25(OH)D concentrations <37.5 nmol/L, though the overall trend 
was not significant (Freedman et al., 2010). In other cohort studies (Cawthon et al., 2010; Eaton et al., 
2011; Hutchinson et al., 2010; Melamed et al., 2008), either no association or an inverse association 
between 25(OH)D concentration and risk for mortality from cancer was reported. A meta-analysis of 
observational  studies  published  up  to  July  2011  showed  no  association  between  25(OH)D 
concentration  and  breast  cancer  (five  studies)  or  prostate  cancer  (11  studies),  and  an  inverse 
association with colorectal cancer (nine studies) (Chung et al., 2011). In RCTs using vitamin D doses 
between 10 and 27.5 µg/day and lasting four to seven years in which cancer of the breast or colon 
were secondary outcomes, there was no evidence of an increased cancer risk in subjects receiving 
vitamin D (Chlebowski et al., 2008; Lappe et al., 2007; Wactawski-Wende et al., 2006). In a nested 
case-control  study  with  participants  from  eight  prospective  cohorts,  there  was  a  significantly 
increased  risk  for  pancreatic  adenocarcinomas  for  subjects  with  25(OH)D  concentrations 
≥100 nmol/L, but the risk pattern was rather peculiar with a flat trend line (risk close to 1 in all other 
categories of 25(OH)D concentration) followed by a steep inflection for the subjects in the highest 
category (Stolzenberg-Solomon et al., 2010). In two US cohorts for which only intake data were 
available, the association between vitamin D intake and pancreatic cancer was inverse (Skinner et al., 
2006).   
Several studies also addressed the relationship between 25(OH)D concentration and cardiovascular 
disease, but no evidence of an increased risk for fatal and non-fatal cardiovascular events associated 
with high concentrations of 25(OH)D was found in observational studies (Cawthon et al., 2010; Eaton 
et al., 2011; Fiscella and Franks, 2010; Grandi et al., 2010; Hutchinson et al., 2010; Jassal et al., 2010; 
Michaelsson et al., 2010; Virtanen et al., 2011). 
On  other  health  outcomes,  an  observational  study  reported  a  significantly  increased  risk  for 
self-reported  fractures  in  black  women  with  25(OH)D  concentrations  ≥49.9 nmol/L  (compared to 
<49.9 nmol/L), whereas the association was inverse for white women (Cauley et al., 2011). In women 
receiving 1 g calcium plus 10 µg vitamin D daily for a mean of seven years, a higher incidence of 
self-reported urinary tract stones was reported compared to those receiving placebo (Wallace et al., 
2011). Plasma or serum 25(OH)D concentrations were not measured in this study. The Panel notes 
that the low dose of vitamin D used, and the nature of the combined nutrient supplementation, do not 
allow the attribution of the reported adverse effect to vitamin D intake per se. Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813  14 
The Panel notes that no studies reported an association between vitamin D intake and increased risk 
for adverse long-term health outcomes, and that studies reporting on an association between 25(OH)D 
concentration  and  all-cause  mortality  or  cancer  are  inconsistent.  The  Panel  also  notes  that  when 
25(OH)D  concentrations  were  associated  with  an  increased  risk  for  adverse  long-term  health 
outcomes in some studies, there was a wide variation in 25(OH)D concentrations associated with the 
adverse effect. The Panel considers that 25(OH)D concentrations cannot be used to characterise the 
risk for adverse long-term health outcomes.  
3.5.4.  Adverse effects of vitamin D intake in pregnant and lactating women 
De-Regil et al. (2012) systematically searched the literature for RCTs which evaluated the effect of 
supplementation with vitamin D alone or in combination with calcium on women during pregnancy. 
Six RCTs published up to October 2011 were included for meta-analysis. The dose of vitamin D used 
in  routine  daily  supplementation  ranged  from  20-30 µg.  The  studies  reported  on  pre-eclampsia, 
nephritic syndrome, and stillbirths or neonatal deaths, and there was no difference in risk between 
pregnant women receiving vitamin D and those receiving placebo. 
Hollis et al. (2011) randomly assigned pregnant women to receive either 10 µg, 50 µg or 100 µg 
vitamin D3/day from 12-16 weeks of gestation until delivery. The primary outcome was change in 
maternal  serum  25(OH)D  concentrations,  but  the  study  also  addressed  the  safety  of  vitamin  D 
supplementation and pregnancy outcomes. Of the 502 women randomised, only 350 were followed 
through delivery, and no attempt was made to assess pregnancy outcomes in those who discontinued 
from the study for reasons other than miscarriage. The number of, and gestational age at, pregnancy 
losses, and the serum 25(OH)D concentrations in those affected, did not differ between the groups 
(n=8, 5, 10 in the groups receiving 10 µg, 50 µg or 100 µg vitamin D3/day, respectively). Mode of 
delivery, pregnancy duration, birth weight and neonatal level of care required after birth also did not 
differ. No information on the nature of adverse events was given in the study, but the authors stated 
that no adverse event was attributed to vitamin D supplementation or serum 25(OH)D concentrations. 
Throughout  the  trial,  the  groups  did  not  differ  with  respect  to  serum  calcium  and  urinary 
calcium-to-creatinine  ratio.  It  was  decided  a  priori  to  discontinue  supplementation  in  women 
exceeding a 25(OH)D concentration of 225 nmol/L as a safety measure. Three women (one in the 
100 µg  vitamin  D3/day  group)  attained  this  threshold  without  accompanying  hypercalcaemia  or 
hypercalciuria.  
In  another  study,  lactating  women  (n=18)  randomly  received  either  40 µg  vitamin  D2+10 µg 
vitamin D3/day or 90 µg vitamin D2+10 µg vitamin D3/day from month 1 through 4 of lactation during 
which  time  they  were  asked  to  limit  sun  exposure  (Hollis  and  Wagner,  2004).  Serum  calcium 
concentrations remained within the normal range and hypercalciuria did not occur. Serum 25(OH)D 
concentrations increased from 69±8 to 90±6 nmol/L in the group receiving 40 µg vitamin D2+10 µg 
vitamin D3/day and from 82±6 to 111±10 nmol/L in the group receiving 90 µg vitamin D2+10 µg 
vitamin D3/day. In the infants, concurrent increases in serum 25(OH)D concentration were observed 
resulting from an increase in vitamin D intake via human milk. In infants whose mothers received the 
lower  vitamin  D  dose,  total  circulating  25(OH)D  concentrations  increased  from  20±3  to 
69±10 nmol/L, whereas concentrations increased from 33±8 to 77±12 nmol/L in infants of mothers 
receiving the higher vitamin D dose.   
In  a  nested  case-control  study,  a  U-shaped  association  was  observed  in  white  (n=77  cases, 
196 controls)  but  not  in  black  (n=34  cases,  105  controls)  nulliparous  women  between  25(OH)D 
concentrations in the first half of pregnancy (<22 weeks) and birth of a small-for-gestational age 
(SGA) infant (Bodnar et al., 2010). In white women, the odds ratio (OR) was 2.1 (95 % CI 1.2-3.8) 
for  a  serum  25(OH)D  concentration  >75 nmol/L  (reference  category  37.5-75 nmol/L).  The  Panel 
notes  that  it  is  unclear  whether  a  one-time  measurement  of  vitamin  D  status  in  early  pregnancy 
reflects vitamin D status throughout pregnancy, that no intake data are available linking vitamin D Tolerable Upper Intake Level of vitamin D 
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intake to an increased risk for an SGA infant, and that only a limited number of possible dietary and 
lifestyle  confounders  were  taken  into  account  in  the  analyses.  Thus,  the  Panel  considers  that  no 
conclusions can be drawn from this study in relation to the effects of vitamin D intake on pregnancy 
outcomes.  
The Panel considers that evidence from one intervention trial in pregnant women receiving vitamin D 
after the period of early organogenesis and from another small trial in lactating women, both using 
doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, did not report adverse events 
for either the mothers or their offspring.   
3.5.5.  Adverse effects of vitamin D intake in infants 
In infants, hypercalcaemia has been associated with single large dose therapies of vitamin D (also 
known as stoss therapy). The potential toxicity associated with stoss therapy is underscored by a 
report  showing  hypercalcaemia  in  a  young  child  who  received the equivalent of four daily stoss 
therapy doses of 15 mg vitamin D each (Barrueto et al., 2005). The Panel notes that no information on 
effects of chronic daily intake relevant for the establishment of a UL can be derived from such case 
reports.  
A number of studies with lower daily doses of vitamin D are available. 
Jeans and Stearns (1938) found retarded linear growth in nine infants up to one year of age who 
received  about  45-112.5  g  vitamin  D/day  in  comparison  with  standard  growth  curves  of infants 
receiving daily vitamin D at doses of 8.5  g or less for a minimum of six months. The infants were 
given either cod liver oil, a cod liver oil concentrate emulsified in cream, or viosterol (vitamin D2) in 
oil.  The  infants  supplemented  with  high  doses  of  vitamin  D  showed  retarded linear growth, and 
increased rates of growth were seen when the dose of vitamin D was reduced to 10-15  g/day. In 
another  study,  Fomon  et  al.  (1966)  compared  13  formula-fed  infants  who  ingested  34.5-54.3  g 
vitamin  D/day  (median  intake  45  g/day)  with  11  infants  who  ingested  8.8-13.8  g/day  (median 
intake 11 µg/day). The infants were enrolled before the age of nine days and were followed-up at ages 
28, 56, 84, 112, 140 and 168 days. A group of 26 breast-fed infants was also followed. No differences 
in linear growth and in serum calcium concentrations were found between groups in this small study. 
Data from a Finnish population-based birth cohort was used to assess retrospectively the association 
between infantile vitamin D supplementation and body height at various time points until adulthood 
(Hyppönen et al., 2011). No association of vitamin D dose (<50 µg/day, n=66; 50 µg/day according to 
the  Finnish  recommendations  at  that  time,  n=8,100;  and  >50 µg/day,  n=407)  in  regularly 
supplemented infants with body length or height at one year (measured), at 14 years (self-reported) 
and in adulthood (self-reported and measured) was reported. No difference in height was observed 
between groups classified according to frequency of supplementation (none, irregular, or regular), but 
again the groups were highly unequally sized. 
In a study from Finland, Ala-Houhala (1985) supplemented breast-fed infants with 0, 10 or 25  g 
vitamin D2/day for 20 weeks (14-17 infants per group). Mothers of infants not taking vitamin D 
received 25  g/day. Two studies were conducted, one starting in January and the other starting in 
July. Mean serum calcium concentrations in infants did not appear to increase throughout the study in 
either group.  
Vervel et al. (1997) studied healthy neonates born from April to July of mothers supplemented (n=22) 
or not supplemented (n=48) with vitamin D during pregnancy. The infants were given supplemental 
vitamin  D2  (either  12.5 or  25 µg/day).  In  addition,  they  were  fed  infant  formulae  chosen  by  the 
mothers and thus varying slightly in vitamin D content (10.7±1.2 µg/L). All 70 infants were followed 
until the age of one month, and 52 infants were followed until three months of age. Mean serum Tolerable Upper Intake Level of vitamin D 
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calcium concentrations did not differ between groups at one and three months of age. Serum calcium 
concentrations at three months ranged from 2.42 to 2.80 mmol/L in infants who received 12.5 µg 
vitamin  D/day  in  addition  to  fortified  infant  formula,  and  from  2.46  to  2.79 mmol/L  in  those 
supplemented with 25 µg vitamin D/day; the percentage of infants presenting with serum calcium 
concentrations  >2.6 mmol/L  was  lower  in  the  higher  vitamin  D  group  compared  to  the  lower 
vitamin D group. 
In  a  randomised  study,  infants  and  toddlers  with  hypovitaminosis  D  (25(OH)D  concentration 
<50 nmol/L) aged between 9 and 23 months were treated for six weeks with either 50 µg vitamin D2 
daily (n=12), 1,250 µg vitamin D2 weekly (n=14), or 50 µg vitamin D3 daily (n=14), and each group 
also received 50 mg calcium/kg body weight per day (Gordon et al., 2008). Small and similar changes 
in mean serum calcium concentrations in the three treatment groups (-3 % for vitamin D2 daily, +3 % 
for vitamin D2 weekly, +1 % for vitamin D3 daily) were reported, as well as a higher overall incidence 
of mild hypercalcaemia at baseline compared to after treatment, but no definition was given as to the 
normal  range  of  calcium  concentrations  in  serum.  All  subjects  with  mild  hypercalcaemia  were 
reported to be asymptomatic. The Panel notes that this was a short study using high vitamin D doses 
for treatment of deficiency, and considers that limited conclusions can be drawn from this study for 
the purpose of this risk assessment. 
The Panel notes that there is historical evidence on retarded growth from one study in infants who 
received various regimens of vitamin D exceeding 45 µg/day up to one year of age, although another 
small study using doses up to 54 µg vitamin D/day until about five months of age did not show such 
an effect. More recent intervention studies using doses up to 25 µg vitamin D/day (plus the amount 
ingested via fortified infant formula) for up to five months after birth did not indicate that these 
intakes were associated with hypercalcaemia in infants. 
3.5.6.  Vitamin D intake and hypercalcaemia in children and adolescents 
Two intervention studies on the effects of vitamin D supplementation on calcaemia in children and 
adolescents from the same geographical area are available in the literature. 
In a randomised “pilot” study, boys and girls aged 10-17 years received for eight weeks starting in 
August either placebo oil (n=9), weekly amounts of 350 µg vitamin D3 as oily preparation (n=8) or 
the same amount of vitamin D3 dissolved in ethanol (n=9). After eight weeks, two boys in the placebo 
group had elevated serum calcium concentrations, and one girl who had received vitamin D3 dissolved 
in  ethanol  had  high  concentrations  of  both  serum 25(OH)D and serum calcium (195 nmol/L and 
2.7 mmol/L, respectively). As serum calcium only slightly exceeded the upper limit of normal for that 
age (2.68 mmol/L), the authors did not consider this as evidence for vitamin D intoxication. Two 
other subjects with high 25(OH)D concentrations (>150 nmol/L) did not have concomitantly elevated 
serum calcium concentrations (Maalouf et al., 2008). 
In a second study by the same authors, healthy girls (n=168) and boys (n=172) aged 10-17 years from 
Beirut  (latitude  33.5°  North)  randomly  received  weekly  either  35 µg  vitamin  D3  (equivalent  to 
5 µg/day), 350 µg vitamin D3 (equivalent to 50 µg/day) or placebo for one year (El-Hajj Fuleihan et 
al., 2006; Maalouf et al., 2008). The primary outcomes were changes in lean mass, bone mineral 
density and bone mineral content. Hypercalcaemia did not occur in the girls who received vitamin D3. 
Three girls (5 %) in the high-dose group had high serum 25(OH)D concentrations at the end of the 
study (257, 402 and 487 nmol/L), but none had concomitant hypercalcaemia (>2.68 mmol/L). Two 
boys (4 %) in the high-dose group had high serum 25(OH)D concentrations at the end of the study 
(157 and 172 nmol/L), but none had concomitant hypercalcaemia. Five boys, of whom three had 
received placebo, one the low and one the high vitamin D dose, had hypercalcaemia. Thus, as cases of 
hypercalcaemia occurred in active and non-active treatment groups, these cases cannot be related to 
supplementation with vitamin D per se. Calcium intake and sun exposure, but not dietary intake of Tolerable Upper Intake Level of vitamin D 
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vitamin D, were measured at baseline and follow-up, but were not reported in relation to adverse 
events.  
The Panel notes that there are only two studies on weekly vitamin D supplementation equivalent to 
daily intakes of 5-50 µg in children and adolescents, and that the mild hypercalcaemia observed in a 
few  subjects  could  not  be  attributed  to  vitamin  D  supplementation.  The  Panel  concludes  that 
vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia in children and adolescents 
aged 10-17 years. 
4.  Dose-response assessment and derivation of a Tolerable Upper Intake Level 
The critical effect of excess intake of vitamin D leading to hypervitaminosis D or vitamin D toxicity is 
hypercalcaemia. Hypercalciuria can be associated with hypercalcaemia, but it can also occur without.  
4.1.  Adults 
Doses of 234-275 µg vitamin D3/day were administered in two studies to 10-15 healthy men for eight 
weeks to about five months without reported hypercalcaemia (Barger-Lux et al., 1998; Heaney et al., 
2003). The Panel considers that a daily vitamin D dose of 250 µg/day (range 234-275 µg/day) reflects 
a NOAEL. The Panel notes that there are a number of uncertainties on whether this estimate of the 
NOAEL covers the range of variation in the sensitivity of the population to possible adverse effects of 
vitamin D over the long term and that it is based only on two studies of short duration (up to five 
months) in small samples of healthy young men with minimal sun exposure. The Panel considers that 
an uncertainty factor of 2.5 is appropriate to take into account these uncertainties.  
Based on a NOAEL of 250 µg/day (range 234-275 µg/day) and the use of an uncertainty factor of 2.5, 
the UL for adults is estimated at 100 µg/day. Supportive evidence for a UL of 100 µg/day is provided 
by randomised controlled studies in which this dose or higher doses were administered to various 
population  groups  (whites,  African  Americans,  pre-  and  postmenopausal  women,  elderly  nursing 
home residents, overweight and obese adults, pregnant and lactating women) for up to 12 months 
without evidence of (persisting) hypercalcaemia or hypercalciuria.   
4.2.  Pregnant and lactating women 
There is no evidence that pregnancy or lactation increase the susceptibility for adverse effects of 
vitamin D intake. The Panel considers that the UL of 100 µg/day for adults also applies to pregnant 
and lactating women. This UL is supported by two studies in pregnant and lactating women, both 
using doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, which did not report 
adverse events for either the mothers or their offspring (Hollis and Wagner, 2004; Hollis et al., 2011). 
4.3.  Infants 
For infants, there is still a paucity of data on which to base a NOAEL or a lowest observed adverse 
effect level (LOAEL). The inconsistent evidence on linear growth from two rather old studies with 
low numbers of infants has been complemented by retrospective data on linear growth from infants in 
Finland (Hyppönen et al., 2011). Other studies on the relationship between vitamin D intake and 
linear growth in infants were not available. 
No new data from intervention studies on hypercalcaemia in healthy infants have emerged since the 
risk assessment undertaken by the SCF in 2003.  Tolerable Upper Intake Level of vitamin D 
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Considering  the  limited  evidence  that  has  become  available  since  the  last  risk  assessment  (SCF, 
2003), the Panel considers that the UL of 25 µg vitamin D/day previously derived for infants from 
0-12 months of age should be retained. 
4.4.  Children and adolescents 
Since  the  previous  risk  assessment  (SCF,  2003),  two  studies  in  children  aged  10-17  years  have 
become  available  (El-Hajj  Fuleihan  et  al.,  2006;  Maalouf  et  al.,  2008).  These  studies  show  that 
vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia in children and adolescents 
aged 10-17 years. While there are no studies at higher intakes, the Panel considers that there is no 
reason to believe that adolescents in the phase of rapid bone formation and growth have a lower 
tolerance  for  vitamin  D  compared  to  adults.  Thus,  the  Panel  proposes  a  UL  for  vitamin  D  of 
100 µg/day for adolescents aged 11-17 years. 
For children aged 1-10 years, no new data from intervention studies have emerged since the last risk 
assessment (SCF, 2003). The Panel considers that there is no reason to believe that children aged 
1-10 years in the phase of rapid bone formation and growth have a lower tolerance for vitamin D 
compared to adults, and proposes a UL for vitamin D of 50 µg/day by taking into account their 
smaller body size. 
4.5.  Summary of Tolerable Upper Intake Levels for vitamin D 
Age (years)  Tolerable Upper Intake Level (UL) for vitamin D ( g/day) 
Children   
  0-1    25 
  1-10    50 
11-17  100 
Adults
1 ≥18  100 
1 The UL for adults also applies to pregnant and lactating women. 
5.  Characterisation of the risk 
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups (i.e., about 25 %, 75 %, 30 % and 8 % of the UL for 
adults, infants, children and adolescents, respectively).  
CONCLUSIONS  
The UL for vitamin D for adults, including pregnant and lactating women, has been established at 
100 µg/day. For children and adolescents, the UL has been set at 50 µg/day for ages 1-10 years, and at 
100 µg/day for ages 11-17 years. For infants up to one year of age, the UL is 25 µg/day.  
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups.   
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APPENDICES 
A.  INTAKE OF VITAMIN D AMONG ADULTS IN EUROPEAN COUNTRIES 
Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods  Women  Austria  (Elmadfa et al., 
2009b) 
24-hour recall  426  < 25  > 35  Pregnant women in 2nd trimester  2.5         
          76  < 25   25  Pregnant women in 2nd trimester  2.1         
          288   25   35  Pregnant women in 2nd trimester  2.6         
          62   35  > 35  Pregnant women in 2nd trimester  3.3         
    Denmark  (Pedersen et al., 
2010) 
7-day record (data collected in 2003-2008)  150   18   24    2.6      7.0   
          340   25   34    2.8      7.6   
          412   35   44    2.9      8.6   
          359   45   54    3.1      9.1   
          326    55    64    3.4        8.4    
          198    65    75    3.4        8.5    
      (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
671   18   49  Non-supplement users  2.0      7.3   
          825   18   49  Supplements users  2.1      7.7   
          280    50    75  Non-supplement users  2.3        7.7    
          599    50    75  Supplements users  2.5        7.9    
    Finland  (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
641   25   74  Usual intakes. Underreporters 
excluded 
6.0      10.8   
    Germany  (MRI, 2008)  24-hour recall + Dietary History  510   19   24    2.0      4.8   
          972   25   34    2.6      6.4   
          2,694   35   50    2.7      6.3   
          1,840    51    64     3.4        8.8    
          1,562    65    80     3.4        8.2    
    Ireland  (IUNA, 2011)  4-day record  255   18   35    2.4      5.8  7.9 
          232   36   50    2.8      7.4  8.5 
          153    51    64     3.3        8.1  10.1 Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods  Women  Italy  (Sette et al., 2010)  Consecutive 3-day food record  1,245   18  < 65  Including fortified food  2.3      7.3   
          316    65    99  Including fortified food  1.8        6.2    
    Poland  (Flynn et al., 
2009) 
24-hour recall  1,656   18   96    3.3      7.9   
    Spain  (Flynn et al., 
2009) 
Two non-consecutive 24-hour recalls (one 
for all, a second for 62 % of the sample) 
895   18   64  Data collected in Catalonia.  1.1      2.4   
    Sweden  (Becker and 
Pearson, 2002) 
7-day record  67   17   24    4.1      7.6   
          128   25   34    4.5      7.5   
          143   35   44    4.7      8.1   
          118   45   54    5.0      9.1   
          68    55    64     5.8        9.8    
          65    65    74     6.1        10.6    
    The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls  347   19   30      2.6    4.9   
          351   31   50      2.8    5.3   
          353    51    69        3.2     5.8    
Foods  Men  Denmark  (Pedersen et al., 
2010) 
7-day record (data collected in 2003-2008)  105    18    24     2.6        5.9    
          234   25   34    3.5      8.6   
          318   35   44    3.8      10.4   
          336   45   54    3.7      9.9   
          336    55    64     4.4        11.5    
          240    65    75     3.9        9.9    
      (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
663   18   49  Non supplement users  2.7      n.a.   
          587   18   49  Supplements users  2.8      9.5   
          363    50    75  Non supplement users  2.9        9.4    
          491    50    75  Supplements users  3.1        9.8    Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods  Men  Finland  (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
637   25   74  Usual intakes. Underreporters 
excluded 
8.2      16.0   
    Germany  (MRI, 2008)  24-hour recall + Dietary History  510   19   24    3.0      7.0   
          690   25   34    3.5      8.0   
          2,079   35   50    3.8      9.7   
          1,633    51    64     4.2        10.9    
          1,469    65    80     4.4        10.6    
    Ireland  (IUNA, 2011)  4-day record  276   18   35    3.1      7.8  9.0 
          205   36   50    3.4      8.3  9.8 
          153    51    64     4.1        10.8  15.6 
    Italy  (Sette et al., 2010)  Consecutive 3-day food record  1,068   18  < 65  Including fortified food  2.6      7.7   
          202    65    99     2.5        7.5    
    Poland  (Flynn et al., 
2009) 
24-hour recall  1,324   18   96    5.7      14.8   
    Spain  (Flynn et al., 
2009) 
Two non-consecutive 24-hour recalls (one 
for all, a second for 62 % of the sample) 
718   18   64  Data collected in Catalonia.  1.5      3.1   
    Sweden  (Becker and 
Pearson, 2002) 
7-day record  67   17   24    5.6      11.1   
          128   25   34    5.6      9.8   
          143   35   44    6.1      11.3   
          118   45   54    6.6      12.1   
          68    55    64     6.6        13.2    
          65    65    74     7.1        12.1    
    The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls  356   19   30      3.5    6.1   
          348   31   50      3.8    6.6   
               351    51    69        4.1     7.0    Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods  Men and 
women 
France  (Dufour et al., 
2010) 
7-day record  1,918   18   79  Non under-reporters. Fortified food 
excluded. 
2.6      5.5  6.7 
    Ireland  (IUNA, 2011)  4-day record  226    65  > 65     3.8        9.4  12.0 
    Portugal  (Lopes et al., 
2006) 
Food frequency questionnaire  478   18   39  Data collected in Porto  3.7      6.6   
          537   40   49    3.6      6.3   
          789    50    64     3.7        6.4    
          585    65  > 65     3.3        6.1    
    United 
Kingdom 
(Bates et al., 
2011) 
4-day record  807   19   64    2.9        8.5 
          224    65  > 65     3.3           9.0 
Supplements  Women  Austria  (Elmadfa et al., 
2009b) 
Quantitative consumption frequency 
questionnaire 
22    18    65  Assessment of supplement 
consumption among 282 adults in 
all Austria (77 supplement users) 
   5.0  5.0       
    Germany  (MRI, 2008)  24-hour recall + Dietary History  18   19   24  Users of vitamin D supplements  5.5      25.1   
          48   25   34  Users of vitamin D supplements  5.4      20.0   
          134   35   50  Users of vitamin D supplements  5.3      15.0   
          135    51    64  Users of vitamin D supplements  7.3        22.0    
            136    65    80  Users of vitamin D supplements  7.7        22.0    
Supplements  Men  Austria  (Elmadfa et al., 
2009b) 
Quantitative consumption frequency 
questionnaire 
15   18   65  Assessment of the consumption of 
supplements among 282 adults in 
all Austria (77 supplement users) 
  2.0  5.0     
    Germany  (MRI, 2008)  24-hour recall + Dietary History  17   19   24  Users of vitamin D supplements  4.2      10.0   
          34   25   34  Users of vitamin D supplements  2.9      5.0   
          90   35   50  Users of vitamin D supplements  4.1      10.0   
          60    51    64  Users of vitamin D supplements  8.5        15.0    
               62    65    80  Users of vitamin D supplements  5.9        15.0    
Foods and 
supplements 
Women  Denmark  (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
825   18   49  Supplements users  7.6      15.0   
          599    50    75  Supplements users  8.3        17.0    Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods and 
supplements 
Women  Finland  (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
641   25   74  Usual intakes. Underreporters 
excluded 
8.3      16.2   
    Ireland  (IUNA, 2011)  4-day record  255   18   35    3.1      8.3  11.8 
          232   36   50    3.5      9.3  13.7 
          153    51    64     6.0        21.3  22.6 
    Norway  (Johansson et al., 
1998) 
Food frequency questionnaire  406   16   79  First quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
5.3         
          406   16   79  Fourth quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
18.5         
    The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls  347   19   30      2.9    6.3   
          351   31   50      3.3    7.9   
          353    51    69        3.8     8.7    
Foods and 
supplements 
Men  Denmark  (Tetens et al., 
2011) 
7-day record and interview  587    18    49  Supplements users  7.8        16.0    
          491    50    75  Supplements users  8.4        16.0    
    Finland  (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
637   25   74  Usual intakes. Underreporters 
excluded 
9.5      18.6   
    Ireland  (IUNA, 2011)  4-day record  276   18   35    3.9      10.4  13.6 
          205   36   50    4.7      12.1  16.9 
          153    51    64     5.7        17.1  24.0 
    Norway  (Johansson et al., 
1998) 
Food frequency questionnaire  379   16   79  First quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
5.1         
          378   16   79  Fourth quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
23.5         Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P95  P97.5 
Foods and 
supplements 
Men  The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls  356   19   30      3.7    6.7   
          348   31   50      4.2    8.0   
               351    51    69        4.4     8.5    
Foods and 
supplements 
Men and 
women 
Ireland  (IUNA, 2011)  4-day record  226    65  > 65     6.9        24.2  29.3 
    United 
Kingdom 
(Bates et al., 
2011) 
4-day record  807   19   64    3.7        12.0 
               224    65  > 65     4.7           14.9 
NB: white lines indicate data for the age-range approximately 19-50 years; grey lines indicate data for the age-range approximately 51 years and over.  
n.a.: not available. Tolerable Upper Intake Level of vitamin D 
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B.  INTAKE OF VITAMIN D AMONG CHILDREN IN EUROPEAN COUNTRIES 
Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
  Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P90  P95  P97.5 
Foods and 
supplements 
Girls  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  198   1   1  Non-breast-fed infants, 
genetically at-risk of type 1 
diabetes 
12.2    15.0       
Foods and 
supplements 
Boys  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  257   1    1  Non-breast-fed infants, 
genetically at-risk of type 1 
diabetes 
12.2     15.1          
Foods and 
supplements 
Boys 
and girls 
The 
Netherlands 
(de Boer et al., 2006)  2-day record (independent days)   55   0.75   0.75  Supplement users  12.5      19.3     
          145   1   1  Supplement users  8.9      14.8     
Foods  Girls  Denmark  (Andersen et al., 
1996) 
7-day record  149   1    3     1.8           3.2    
      The 
Netherlands 
(Ocke et al., 2008)  2-day record (independent days)  313   2    3     1.8           3.3    
Foods  Boys  Denmark  (Andersen et al., 
1996) 
7-day record  129   1    3     1.7           2.4    
      The 
Netherlands 
(Ocke et al., 2008)  2-day record (independent days)  327   2    3     1.8           3.0    
Foods  Boys 
and girls 
Greece  (Manios et al., 2008)  3-day record (weighed food records 
and 24 h recall or food diaries) 
2,317   1    5  Non-under-reporters. Possible 
inclusion of supplements not 
mentioned 
5.6        11.9       
      Italy  (Sette et al., 2010)  Consecutive 3-day food records 
 
52   0  < 3  Including fortified food  1.8           5.4    
      United 
Kingdom 
(Bates et al., 2011)  4-day food diary  219   1.5    3     1.9              10.6 
Foods and 
supplements 
Girls  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  118   2    2  Genetically at-risk children of 
type 1 diabetes 
9.0     12.6          
               235   3    3     6.9     10.0          
      The 
Netherlands 
(Ocke et al., 2008)  2-day record (independent days)  313   2    3     4.7           10.0    
Foods and 
supplements 
Boys  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  112   2    2  Genetically at-risk children of 
type 1 diabetes 
8.7     11.7          
               236   3    3     7.1     9.5          
      The 
Netherlands 
(Ocke et al., 2008)  2-day record (independent days)  327   2    3     4.4           8.7    
Foods and 
supplements 
Boys 
and girls 
The 
Netherlands 
(de Boer et al., 2006)  2-day record (independent days)   251   1.5    1.5  Supplement users  6.7        8.1       
      United 
Kingdom 
(Bates et al., 2011)  4-day food diary  219   1.5    3     2.3              11.8 Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
  Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P90  P95  P97.5 
Foods  Girls  Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record  301   5   12    1.6        4.4  5.2 
    The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
151   7   8      2.3      4.4   
          352   9   13      2.3      4.5   
Foods  Boys  Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record  293   5    12     1.4           3.7  4.4 
    The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
153   7   8      2.3      4.3   
               351   9    13        2.7        5.0    
Foods  Boys 
and girls 
Denmark  (Pedersen et al., 
2010) 
7-day record  903   4   14    2.3        5.9   
    Italy  (Sette et al., 2010)  Consecutive 3-day food records  52   3  < 10  Including fortified food  2.0        5.1   
    Germany  (Flynn et al., 2009)  3-day record  1,234   6   11    1.8        4.0   
    Poland  (Flynn et al., 2009)  24-hour recall  455   4   10    2.3        5.9   
    Spain  (Flynn et al., 2009)  24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
723   4   10    1.4        2.9   
    The 
Netherlands 
(Flynn et al., 2009)  2-day record (independent days)  639   4   6  Including fortified foods  1.9        3.1   
    United 
Kingdom 
(Bates et al., 2011)  4-day food diary  423   4   10    1.9          4.1 
Foods and 
supplements 
Girls  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  247   4    4  Genetically at-risk children of 
type 1 diabetes 
6.1     8.3          
          349   6   6    5.5    6.6       
    The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
151   7   8      2.5      5.8   
               352   9    13        2.5        5.5    
Foods and 
supplements 
Boys  Finland  (Kyttälä et al., 2008; 
2010) 
3-day record  307   4    4  Genetically at-risk children of 
type 1 diabetes 
5.9     7.7          
          364   6   6    6.3    7.7       Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
  Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P90  P95  P97.5 
Foods and 
supplements 
Boys  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
153   7   8      2.8      6.3   
               351   9    13        3.0        6.3    
Foods and 
supplements 
Boys 
and girls 
Germany  (Flynn et al., 2009)  3-day record  1234   6   11    1.8        5.0   
    Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record  594   5   12    2.3        6.4   
    Spain  (Flynn et al., 2009)  24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
723   4   10  Including fortified food  1.8        3.0   
    Sweden  (Enghardt-Barbieri et 
al., 2006) 
4-day record  590   4   4    6.6        15.4   
          889   8   9    5.0        10.4   
          1,016   11   12    4.6        10.1   
    The 
Netherlands 
(Flynn et al., 2009)  2-day record (independent days)  639   4   6    2.6        5.3   
          639   4   6  Including fortified foods  2.7        5.5   
      United 
Kingdom 
(Bates et al., 2011)  4-day food diary  423   4    10     2.6              7.3 
Foods  Girls  Belgium  (Sioen et al., 2007b)  7-day record  212   13    18  Data collected in the region of 
Ghent in Flanders. 
2.5           4.9    
      Denmark  (Pedersen et al., 
2010) 
7-day record  134   14    17     1.9           5.0    
      Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record  217   13    17     1.8           4.5  6.0 
      Italy  (Sette et al., 2010)  Consecutive 3-day food records  139   10  < 18  Including fortified food  2.4           6.7    
      The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
354   14    18        2.4        4.6    Tolerable Upper Intake Level of vitamin D 
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Nutrient 
source  Sex  Country  Reference  Dietary assessment method  n 
  Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded  Mean  Median  P75  P90  P95  P97.5 
Foods  Boys  Belgium  (Sioen et al., 2007b)  7-day record  129   13    18  Data collected in the region of 
Ghent in Flanders. 
4.05           7.6    
      Denmark  (Pedersen et al., 
2010) 
7-day record  101   14    17     3.0           6.8    
      Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record  224   13    17     2.4           6.0  7.5 
      Italy  (Sette et al., 2010)  Consecutive 3-day food records  108   10  < 18  Including fortified food  2.6           7.7    
      The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
352   14    18        3.1        5.5    
Foods  Boys 
and girls 
Germany  (Flynn et al., 2009)  3-day record  1,272   12    17    2.4           5.5    
    Spain  (Flynn et al., 2009)  24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
1,137   11    17    1.6           3.0    
      United 
Kingdom 
(Bates et al., 2011)  4-day food diary  453   11    18     2.1              5.5 
Foods and 
supplements 
Girls  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
354   14    18        2.6        5.4    
Foods and 
supplements 
Boys  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
352   14    18        3.3        6.1    
Foods and 
supplements 
Boys 
and girls 
Germany  (Flynn et al., 2009)  3-day record  1,272   12    17     2.5           6.3    
      Ireland  (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record  441   13    17     2.7           7.6    
    Poland  (Flynn et al., 2009)  24-hour recall  581   11    17     4.0           9.7    
      Spain  (Flynn et al., 2009)  24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
1,137   11    17  Including fortified food  1.9           3.2    
      United 
Kingdom 
(Bates et al., 2011)  4-day food diary  453   11    18     2.3              6.5 
NB: First white section: infants. First grey section: ~1-3 years. Second white section: older children. Second grey section: ~adolescents. 
 Tolerable Upper Intake Level of vitamin D 
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C.   VITAMIN D INTAKE AND HYPERCALCAEMIA IN ADULTS 
Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Zittermann et 
al., 2009 
 
Bad 
Oeynhausen, 
Germany 
(latitude 52°N) 
Rando-
mised, 
double-
blind, 
placebo- 
controlled 
12 
(starting 
December) 
200 
healthy 
overweight 
adults 
18-70  62 m  165  83.3 µg vitamin 
D3/day  
No   t0: 2.36±0.08 t12: 
2.38±0.10 
 
Δ: 0.02±0.09 
t0: 30.0±17.5  
t12: 85.5±57.5  
 
Δ: 55.5±55.8 
t0: 2.38±0.10 
t12: 2.40±0.25 
 
Δ: 0.02±0.24 
t0: 30.3±20.1 
t12: 42.0±35.0 
 
Δ: 11.8±36.3 
No   
Narang et al., 
1984 
 
Ajmer, India 
(latitude 26°N) 
Inter-
vention 
trial 
3 (season not 
reported) 
30 
healthy 
adults 
21-60  both  not reported  10, 20, 30, 
60, or 95 µg 
vitamin D/day   
 
 
No  60 µg D/day: 
t0: 2.43±0.13 
t3: 2.62±0.22 
 
95 µg D/day: 
t0: 2.46±0.09 
t3: 2.83±0.21 
Not reported  10 µg D/day: 
t0: 2.4±0.06 
t3: 2.5±0.13 
Not reported  Not reported   Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Aloia et al., 
2008 
 
Long Island in 
NY, USA 
(latitude 40°N) 
Rando-
mised, 
double-
blind, 
placebo-
controlled 
6 
(3 successive 
winters 
November - 
March) 
138 white 
(76) and 
African-
American 
(62) 
18–65  both  111  Dose of vitamin 
D3 based on 
initial 
25(OH)D 
concentration 
and adjusted at 
week 9 and week 
18: 
 
dose range up to 
week 9:  
50-100 µg/day,  
 
subsequent dose 
range: 20-
170 µg/day, 
  
median dose: 
95 µg vitamin 
D3/day  
No  t6: < 2.65  To obtain and 
maintain serum 
25(OH)D  
>80 nmol/L and 
< 140 nmol/L 
throughout the 
study 
t6:< 2.65  Δ: 19.5±16.0  No  
 
4 patients with 
hypercalciuria 
on several 
occasions 
equally often 
in vitamin D 
and placebo 
group 
Vieth et al., 
2001 
 
Toronto, 
Canada 
(latitude 43°N) 
Rando-
mised 
5 
(starting 
between 
January and 
February) 
73 
healthy 
adults 
18-56  both  61 
completed 
≥1 month 
25 or 100 µg/day 
D3 
No  mean <2.45,  
all subjects 
remained within 
reference range 
(2.2-2.6) 
100 µg/day: 
t0: 37.9±13.4 
 
plateau after 3 
months at mean 
(range) of 96 
(69-125) 
n/a  n/a  No 
 
On a group 
basis, no 
change from 
baseline in 
urinary molar 
Ca:creatinine 
ratios in 
randomly 
collected urine 
samples. In 1 
subject on 
100 µg/day D3, 
hypercalciuria 
occurred in 2 
of 6 measure-
ments, but 
time points not 
specified. Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Relative 
number of 
occurrences of 
hypercalciuria 
across the 
entire follow-
up period was 
not different 
between 
groups. 
Tjellesen et al., 
1986 
 
Copenhagen, 
Denmark 
(latitude 55°N) 
Rando-
mised, 
double-
blind 
uncon-
trolled 
8 weeks 
(September-
November) 
19 
healthy 
premeno-
pausal 
women 
22-49  f  19  97 µg/day D2 or 
110 µg/day D3 
500  97 µg/day D2: 
t0: 2.46±0.03 
t8: 2.46±0.01 
 
110 µg/day D3: 
t0: 2.46±0.02 
t8: 2.51±0.02, 
p<0.02, 
mean±SEM 
97 µg/day D2: 
t0: 75 (55-96) 
t8: 89 (49-121) 
 
110 µg/day D3: 
t0: 77 (46-100) 
t8: 113 (77-138), 
median (range) 
n/a  n/a  Not reported   
Gallagher et 
al., 2012 
 
Omaha, 
Nebraska 
(latitude 41°N) 
Rando-
mised, 
placebo-
controlled 
12 
(screening in 2 
successive 
years in April 
or January to 
May, enroll-
ment on 
average 5 
weeks after 
screening) 
163 
healthy 
postmeno-
pausal white 
women with 
25(OH)D 
<50 nmol/L 
 
57-90  f  147  0, 12.6, 22.8, 
38.3, 64.8, 
73.7, 105.2, or  
123.4 µg/day D3 
(analysed doses) 
Yes, to 
obtain a 
total Ca 
intake of 
1,200-
1,400 
105.2 µg/day D3: 
t0: 2.35±0.1 
t12: not reported 
 
123.4 µg/day D3: 
t0: 2.37±0.075 
t12: not reported 
 
105.2 µg/day D3: 
t0: 37.2±9.2 
t12: 112.9 
 
123.4 µg/day D3: 
t0: 38.6±9.1 
t12: 115.0 
 
(Values at 12 
months 
calculated on the 
basis of the 
estimated dose-
response curve) 
t0: 2.37±0.1 
t12: not reported 
 
t0:37.7±9.1 
t12:54.5 
 
(Values at 12 
months 
calculated on the 
basis of the 
estimated dose-
response curve) 
5 subjects ≥2.7 
mmol/L, 1 in 
highest dose 
group, others on 
12.6, 22.8, 
64.8 µg D3/day. 
16 subjects ≥2.5 
mmol/L, 2 in 
highest dose 
group, rest in all 
other groups 
including 
placebo; all 
normal at repeat 
testing within 2 
weeks 
19 subjects 
with 
hypercalciuria 
(>400 mg 
Ca/day), 2 in 
highest dose 
group, rest in 
all other 
groups 
including 
placebo, 
normal at 
repeat testing 
in all but 3 
subjects in 
which Ca or 
Ca+D3 was Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
then 
withdrawn 
Mocanu et al., 
2009 
 
Iasi, Romania 
(latitude 47°N) 
Uncon-
trolled 
12 
(November-
December) 
45 
nursing 
home 
residents 
58-89  both  40  125 µg/day D3 
via fortified 
bread 
320  t0: 2.29±0.15 
(2.1-2.65) 
 
t12: 2.28±0.15 
(1.9-2.55) 
t0: 28.8±9.9 
t12: 126.4±37.3 
(slightly different 
values reported 
in abstract) 
Δ: 98.0 (median) 
n/a  n/a  No  3 subjects with 
molar 
Ca:creatinine 
ratio >1 on one 
occasion at 6 
or 9 months in 
the study 
Jorde et al., 
2010  
(also described 
in Sneve et al., 
2008) 
 
Tromso, 
Norway 
(latitude 69°N) 
Rando-
mised, 
double-
blind, 
placebo- 
controlled 
12 
(starting 
November) 
438 over-
weight or 
obese adults 
21-70  both  330  0, 71, or 143 
µg/day D3 
500  71 µg/day D3: 
t0: 2.32±0.11 
Δ: -0.01±0.11 
 
143 µg/day D3: 
t0: 2.30±0.11 
Δ: 0.00±0.12 
71 µg/day D3: 
t0: 56.7±21.2 
Δ: +42.8±22.5 
 
143 µg/day D3: 
t0: 58.7±21.2 
Δ: +79.3±31.2 
t0: 2.31±0.10 
Δ: -0.01±0.11 
t0: 58.8±21.0 
Δ: -1.6±16.8 
3 excluded 
because of 2 
serum 
measurements 
>2.6 mmol/L (1 
in Ca-only group, 
2 in Ca + low 
D3), 4 subjects 
with transient 
increase in serum 
Ca (1 in Ca-only, 
3 in Ca + high 
D3) who 
remained in 
study 
 Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Grimnes et al., 
2012 
 
Tromso, 
Norway 
(latitude 69°N) 
Rando-
mised, 
double-
blind 
12 
(subjects were 
asked to report 
on mean time 
spent outdoors 
between 10 
AM and 3 PM 
in March–
April and 
September 
and between 8 
AM and 8 PM 
in June–
August) 
297 
postmeno-
pausal 
women with 
reduced 
bone mineral 
density 
50-80  f  275  20 or 163 µg/day 
D3 
1,000  20 µg/day D3: 
t0: 2.36±0.07 
Δ: 0.00±0.10 
 
163 µg/day D3: 
t0: 2.36±0.09 
Δ: 0.02±0.09 
20 µg/day D3: 
t0: 71.2±22.3 
Δ: +18.0±18.9 
 
163 µg/day D3: 
t0: 70.7±23.0 
Δ: +114.7±34.6 
n/a  n/a  Modest 
hypercalcaemia 
(defined as serum 
calcium of 2.6-
2.8 mmol/L) was 
reported for 9 
women in the 
high-dose group 
and 4 women in 
the low-dose 
group, at serum 
25(OH)D 
concentrations 
across a range of 
64-256 nmol/L, 
all resolved at 
retesting 
 
Berlin et al., 
1986 
(also described 
in Berlin T and 
Björkhem I, 
1987) 
 
Stockholm, 
Sweden 
(latitude 59°N) 
Control-
led 
7 weeks 
(March-April) 
24 
healthy 
Swedish 
22-47  m  24  193 µg/day D3  No  t0: 2.47±0.03 
t7: 2.49±0.03 
 
(mean±SEM) 
t0: 38±4 
t7: 123±5 
 
(mean±SEM) 
t0: 2.50±0.02 
t7: 2.44±0.04 
 
(mean±SEM) 
t0: 37±2 
t7: 48±3 
 
(mean±SEM) 
Not reported  No side effects 
were recorded. 
Heaney et al., 
2003 
 
Omaha, USA 
(latitude 41°N) 
Rando-
mised, 
controlled 
20 weeks: 
(winter 
months of 2 
successive 
years: late 
October-late 
February/ 
early March) 
67 
healthy 
adults 
38.7±11.2  m  not reported 0, 20.9, 137.5, or 
275 µg/day D3 
(analysed doses) 
No  t0: 2.4, 
no change 
from baseline at 
any time point 
(1, 3, 6, 10, 20 
weeks) for 
subjects in two 
highest dose 
groups 
t0: 70.3±19.9 
for all subjects 
 
137.5 µg/day: 
Δ: +91.9±37.6 
 
275 µg/day: 
Δ: +159.4±62.4 
Not reported 
 
 
Δ: -11.4±17.7  No  
(all 31 subjects in 
two highest dose 
groups <2.6 
mmol/L) 
 Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Rickers et al., 
1982 
 
Glostrup, 
Denmark 
(latitude 54°N) 
Rando-
mised, 
controlled 
24 weeks  31 
patients 
under 
treatment 
with 
prednisone 
for various 
diseases 
27-81  both  31  321 µg/day D2 
(in combination 
with prednisone 
and 50 mg/day 
sodium fluoride) 
4,500 
calcium 
phosphate 
t0: 2.48±0.05 
t24:2.46±0.03   
 
(mean±SEM) 
25(OH)D2 
t0: 4.2±1.2 
t24: 145.3±19.0 
 
25(OH)D3 
t0: 38.4±4.2 
t24: 10.2±1.2 
 
(mean±SEM) 
t0: 2.50±0.04 
t24:2.44±0.05 
 
(mean±SEM) 
25(OH)D2 
t0: 8.7±2.2 
t24: 7.2±3.5 
 
25(OH)D3 
t0: 42.7±5.5 
t24: 34.4 ±5.5 
 
(mean±SEM) 
Not reported   
Hasling et al., 
1987 
 
Aarhus, 
Denmark 
(latitude 56°N) 
Uncon-
trolled 
5 years 
(mean 
observation 
time 2.8 years) 
163 
consecutive 
patients with 
spinal crush 
fracture 
osteopo-rosis 
16-84  both  43  450 µg/day D2 
(in combination 
with 60 mg/day 
sodium fluoride) 
1,800  t0: 2.50±0.1 
t5y:2.45±0.06, 
p<0.001, 
no change at 6-
12 months 
(n=152 patients) 
levels increased 
during treatment 
(reported in 
Charles et al., 
1985) 
n/a  n/a  No 
hypercalcaemic 
episodes were 
observed 
Urinary Ca 
excretion did 
not change 
during 
treatment. 
Barger-Lux et 
al., 1998 
 
Omaha, USA 
(latitude 41°N) 
Open-label  8 weeks 
(Jan-April) 
38 
healthy 
20-37  male  38  35, 234, or 1,269 
µg/day D3  
 
(analysed doses) 
No  Not reported  t0 in all 116 
subjects in study: 
67±25 
  
35 µg D3/day: 
Δ: +28.6±5.3  
 
234 µg D3/day: 
Δ: +146.1±12.0  
 
1,269 µg D3/day: 
Δ: +643.0±42.7 
(mean±SEM) 
n/a  n/a  “no 
hypercalcaemia 
was detected in 
post-treatment 
testing of our 
vitamin D3- 
treated subjects” 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Schwartzman 
and Franck, 
1987 
 
New York, 
USA 
(latitude 42°N) 
Case 
reports 
6 weeks – 
5 years 
4 patients 
with 
osteoporo-sis 
(3) or 
osteomala-
cia (1);  
2 of 4 with 
corticoid 
therapy;  
1 with renal 
insufficien-
cy 
42-77  f  n/a  1,250 µg/? 
 
 
179 µg/day D2 
 
 
1,250 µg/day 
 
 
357 µg/day D2 
 
Yes, dose 
unknown 
 
Yes, dose 
unknown 
 
400 
 
 
400 
3.35 
 
 
2.88 
 
 
3.75 
 
 
Not reported 
354 
 
 
Not reported 
 
 
339 
 
 
634 
 
 
n/a  n/a  Yes   
Selby et al., 
1995 
 
 
Manchester, 
UK  
(latitude 53°N) 
Case 
reports 
10 years 
 
 
2 years 
 
 
10 years 
 
 
13 years 
 
 
unknown 
 
 
2 years 
6 
patients with 
hypopara-
thyroidism, 
hypophos-
phataemic 
rickets, 
coelic 
disease, 
paraesthe-
siae or 
unknown 
reason for 
vitamin D 
therapy 
51 
 
 
14 
 
 
47 
 
 
52 
 
 
36 
 
 
57 
both  n/a  2,500 µg/day 
 
 
5,000 µg/day 
 
 
2,500 µg/day 
 
 
2,500 µg/day 
 
 
unknown 
 
 
5,000 µg/day 
Not 
reported 
3.19 
 
 
3.00 
 
 
3.24 
 
 
3.31 
 
 
3.07 
 
 
3.77 
 866 
 
 
 802 
 
 
1005 
 
 
 533 
 
 
 643 
 
 
1203 
n/a  n/a  Yes   Tolerable Upper Intake Level of vitamin D 
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Author  Study 
Design 
Duration  Number at 
entry and 
type of 
subjects 
Age range  Sex  Completers  Vitamin D 
supplement 
Ca
 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group  Hyper-
calcaemia 
Remarks 
  
(months)     (years)  (m/f)  (n) 
Equivalent daily 
dose (µg/day)  (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L)  (Yes / No) 
 
Davies and 
Adams, 1978 
 
Manchester, 
UK  
(latitude 53°N) 
Case 
reports 
Several years 
 
 
7 years 
 
10 years 
 
4 months 
 
3 years 
 
2 years 
 
9 months 
 
10 years 
8 
patients with 
hypopara-
thyroidism, 
Paget's 
disease, 
arthritis, vit. 
D-resistant 
rickets, 
osteopo-
rosis, or 
symptoms 
suggesting 
carpal-tunnel 
syndrome 
59 
 
 
71 
 
51 
 
55 
 
60 
 
15 
 
30 
 
44 
both  n/a  1,250-2,500 µg 
D2/day 
 
3,750 µg D2/day  
 
2,500 µg/day 
 
3,750 µg/day 
 
1,250 µg/day 
  
5,000 µg/day 
 
1,250 µg/day  
 
2,500 µg/day  
Yes, dose 
not 
specified; 
not 
reported 
for all 
other cases 
3.1 
 
 
4.5 
 
3.75 
 
3.9 
 
4.3 
 
3.1 
 
4.0 
 
3.1 
Not reported 
 
 
1,123 
 
998 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
n/a  n/a  Yes   
Rizzoli et al., 
1994 
 
Geneva, 
Switzerland 
(latitude 69°N) 
Case 
reports 
96 weeks 
 
 3 weeks 
 
74 weeks 
 
12 weeks 
 
 4 weeks 
 
 4 weeks 
6 
patients with 
osteoporo-
sis, or 
hypopara-
thyroidism 
72 
 
56 
 
50 
 
66 
 
84 
 
79 
both  n/a  2,143 µg/day D3 
 
7,500 µg/day D3 
 
7,500 µg/day D3 
 
1,071 µg/day D3 
 
7,500 µg/day D3 
 
7,500 µg/day D3 
Not 
reported 
3.55 
 
2.83 
 
3.30 
 
2.53 
 
4.59 
 
3.29 
221 
 
801 
 
1,692 
 
374 
 
650 
 
621 
n/a  n/a  Yes, in all but 
one patient who 
was considered 
vitamin D 
intoxicated on 
the basis of signs 
of enhanced bone 
resorption, 
history of 
excessive vit. D 
intake and 
increased 
25(OH)D 
concentration 
 
n/a: not applicable; m: males; f: females Tolerable Upper Intake Level of vitamin D 
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GLOSSARY AND ABBREVIATIONS 
25(OH)D  25-Hydroxy-vitamin D (sum of 25-Hydroxy-vitamin D2 and 25-Hydroxy-vitamin D3) 
1,25(OH)2D  Active metabolite/vitamin D hormone 
BMI    Body mass index 
CI    Confidence interval 
CYP    Cytochrome P 
IoM    Institute of Medicine 
LOAEL  Lowest observed adverse effect level 
NHANES  United States National Health and Nutrition Examination Survey 
NOAEL  No observed adverse effect level 
OR    Odds ratio 
RCT    Randomised controlled trial 
SCF    Scientific Committee on Food 
SEM    Standard error of the mean 
SGA    Small-for-gestational age 
UL    Tolerable Upper Intake Level 
UV    Ultraviolet 
Vitamin D2  Ergocalciferol (also termed viosterol) 
Vitamin D3  Cholecalciferol 